Avidity Partners Management
Latest statistics and disclosures from Avidity Partners Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are SGEN, MRK, ABBV, MCK, BMRN, and represent 29.45% of Avidity Partners Management's stock portfolio.
- Added to shares of these 10 stocks: SGEN (+$80.50M), MRK (+$37.85M), MCK (+$32.87M), ABBV (+$29.18M), BMRN (+$25.52M), REGN (+$24.41M), CAH (+$24.21M), BIIB (+$19.62M), EXEL (+$18.70M), BHVN (+$18.38M).
- Started 31 new stock positions in CAH, CCXI, MRK, REGN, Allergan, NERV, EXEL, CVS, GILD, HUM.
- Reduced shares in these 10 stocks: BAX (-$13.80M), , ZBH (-$8.16M), , AXNX (-$5.76M), NXTC (-$5.24M), ABEO, DXCM, , COLL.
- Sold out of its positions in ABEO, ARAV, AXNX, BAX, DXCM, EW, EXAS, HCA, MDGL, NLTX. NXTC, RLMD, RCKT, ZBH.
- Avidity Partners Management was a net buyer of stock by $581.61M.
- Avidity Partners Management has $723.59M in assets under management (AUM), growing by 355.98%.
Portfolio Holdings for Avidity Partners Management
Companies in the Avidity Partners Management portfolio as of the March 2020 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Share Count | Change in Shares | Price |
|---|---|---|---|---|
| Seattle Genetics (SGEN) | 11.13 | 697.70k | NEW | 115.38 |
| Merck & Co (MRK) | 5.23 | 492.00k | NEW | 76.94 |
| Abbvie (ABBV) | 5.02 | 477.00k | +407% | 76.19 |
| McKesson Corporation (MCK) | 4.54 | 243.00k | NEW | 135.26 |
| BioMarin Pharmaceutical (BMRN) | 3.53 | 302.00k | NEW | 84.50 |
| Regeneron Pharmaceuticals (REGN) | 3.37 | 50.00k | NEW | 488.30 |
| Cardinal Health (CAH) | 3.35 | 505.00k | NEW | 47.94 |
| Mirati Therapeutics (MRTX) | 3.13 | 295.00k | +360% | 76.87 |
| Catalent (CTLT) | 2.95 | 411.00k | +346% | 51.95 |
| Momenta Pharmaceuticals (MNTA) | 2.93 | 780.00k | +290% | 27.20 |
| Biogen Idec (BIIB) | 2.71 | 62.00k | NEW | 316.39 |
| Exelixis (EXEL) | 2.58 | 1.09M | NEW | 17.22 |
| Biohaven Pharmaceutical Holding (BHVN) | 2.54 | 540.00k | NEW | 34.03 |
| Alector (ALEC) | 2.38 | 714.00k | NEW | 24.13 |
| Aurinia Pharmaceuticals (AUPH) | 2.37 | 1.18M | +409% | 14.51 |
| CVS Caremark Corporation (CVS) | 2.27 | 277.00k | NEW | 59.33 |
| ACADIA Pharmaceuticals (ACAD) | 2.08 | 357.00k | +561% | 42.25 |
| Gilead Sciences (GILD) | 2.07 | 200.00k | NEW | 74.76 |
| Acceleron Pharma (XLRN) | 2.06 | 166.00k | NEW | 89.87 |
| Alexion Pharmaceuticals (ALXN) | 1.99 | 160.00k | NEW | 89.79 |
| Dynavax Technologies (DVAX) | 1.87 | 3.82M | +390% | 3.53 |
| Kadmon Hldgs (KDMN) | 1.64 | 2.83M | +240% | 4.19 |
| Axsome Therapeutics (AXSM) | 1.60 | 197.00k | NEW | 58.83 |
| Cigna Corp (CI) | 1.59 | 65.00k | +116% | 177.18 |
| Uniqure Nv (QURE) | 1.55 | 237.00k | +330% | 47.45 |
| Moderna (MRNA) | 1.51 | 365.00k | NEW | 29.95 |
| Humana (HUM) | 1.43 | 33.00k | NEW | 314.03 |
| Horizon Therapeutics (HZNP) | 1.36 | 333.00k | +122% | 29.62 |
| Chemocentryx (CCXI) | 1.31 | 236.00k | NEW | 40.18 |
| Minerva Neurosciences (NERV) | 1.19 | 1.43M | NEW | 6.02 |
| Neurocrine Biosciences (NBIX) | 1.17 | 98.00k | +196% | 86.55 |
| Vertex Pharmaceuticals Incorporated (VRTX) | 1.12 | 34.00k | -15% | 237.94 |
| Sarepta Therapeutics (SRPT) | 1.08 | 80.00k | NEW | 97.83 |
| Ligand Pharmaceuticals In (LGND) | 1.03 | 102.00k | NEW | 72.72 |
| Ironwood Pharmaceuticals (IRWD) | 1.02 | 735.00k | NEW | 10.09 |
| Verastem (VSTM) | 1.02 | 2.79M | NEW | 2.64 |
| Charles River Laboratories (CRL) | 0.99 | 57.00k | NEW | 126.21 |
| Allergan | 0.98 | 40.00k | NEW | 177.10 |
| Aerie Pharmaceuticals (AERI) | 0.95 | 507.00k | NEW | 13.50 |
| Ascendis Pharma A S (ASND) | 0.93 | 60.00k | +42% | 112.62 |
| Immunomedics (IMMU) | 0.92 | 493.00k | +252% | 13.48 |
| Amarin Corporation (AMRN) | 0.90 | 1.62M | NEW | 4.00 |
| Esperion Therapeutics (ESPR) | 0.89 | 205.00k | +57% | 31.53 |
| Coherus Biosciences (CHRS) | 0.86 | 382.00k | +78% | 16.22 |
| Aimmune Therapeutics (AIMT) | 0.81 | 408.00k | NEW | 14.42 |
| Anika Therapeutics (ANIK) | 0.67 | 168.00k | NEW | 28.91 |
| Bioxcel Therapeutics (BTAI) | 0.65 | 211.00k | NEW | 22.35 |
| Flamel Technologies Sa (AVDL) | 0.42 | 382.00k | NEW | 7.94 |
| Sunesis Pharmaceuticals Inc Ne (SNSS) | 0.25 | 4.31M | +207% | 0.41 |
| Collegium Pharmaceutical Inc Common Stock Usd (COLL) | 0.04 | 17.00k | -90% | 16.35 |
Download CSV 
Past Filings by Avidity Partners Management
View past SEC 13F filings by Avidity Partners Management
- Avidity Partners Management 2019 Q4 amended filed June 17, 2020
- Avidity Partners Management 2020 Q1 filed May 15, 2020
- Avidity Partners Management 2019 Q4 filed Feb. 14, 2020